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Abstract
Glioblastoma (GBM), a WHO grade IV brain tumor, is an aggressive tumor with 
poor prognosis; even with current standard care of triple therapy, consisting of 
surgical resection, chemo and radiation therapy, the patients’ median survival time 
is only approximately 15 months. Recent practice shows that immunotherapy made 
some progress in some other solid tumors, like melanoma or non-small cell lung 
cancer. This chapter is going to review some advances in immunotherapy for GBM.
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1. Introduction
Glioblastoma (GBM), a World Health Organization (WHO) designed grade IV 
tumor, is an aggressive and most lethal form of brain tumor with extremely poor 
prognosis. Although there exists a standard triple therapy (surgical, chemo and 
radiation), the average survival time for patients with GBM is less than 2 years. Due 
to the presence of blood-brain barrier (BBB), a naturally made special structure 
of the vascular wall inside brain parenchyma, it allows only smaller molecules get 
through the BBB into brain parenchyma, which makes it even more difficult for 
the chemotherapeutic agent to reach the target tumor cells. In addition, due to the 
infiltration nature of this tumor, surgical resection with GTR (gross total resec-
tion) without damage the brain function is almost impossible to archive. Radiation 
therapy may produce some partial control of the tumor; at the same time, it not 
only induces radiation necrosis but also causes additional mutation of the tumor. 
On the other hand, in contrast to mutations of many other solid tumors from other 
organ systems, most glioma-associated mutations offer slightly better prognosis for 
the patients, making the target therapy to those mutations less significant and less 
important. As mentioned above, it is vitally important and necessary to develop a 
minimally invasive and greatly effective method for treating the glioblastoma. In 
this regard, novel GBM treatments including immunotherapy are being investigated 
[1]. Key challenges in glioma-specific immunotherapy as with many other cancers 
are the limited immunogenicity of the cancer cells and the immunosuppressive 
environment of the tumor. Although specific antigens have been identified in sev-
eral cancers, brain tumors, such as GBM, are considered poorly immunogenic [1]. 
In addition, the tumor’s heterogeneity and its consistent mutations may contribute 
further to its poor immunogenicity [1].
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Immunotherapy has garnered increasing support in recent years as a treat-
ment for brain tumors. The immune system has a tremendous capacity for 
targeting and eliminating tumor cells while sparing normal tissues. Following 
decades of preclinical development and success in other solid and blood-borne 
neoplasms, many immunotherapies are now being investigated in patients with 
GBM. Immunotherapeutic classes currently under investigation in patients with 
GBM include various vaccination strategies, adoptive T-cell immunotherapy, 
immune checkpoint blockage, monoclonal antibodies, and cytokine therapy. Trails 
include patients with either primary or recurrent GBM.
2. Vaccine therapy
2.1 Adoptive T-cell immunotherapy (ALT)
Over the past decade, the FDA has approved emerging immunotherapies for 
a variety of cancers [2]. At present, many studies have proven that the brain is 
no longer an immune-exempt organ, and there are many interactions between 
tumors and the brain immune system [3, 4]. The fully functional T-cell bank plays 
an important part in maintaining immune surveillance and initiating antitumor 
immune responses. However, glioblastoma (GBM) is particularly good at destroying 
antitumor immunity and causing severe T-cell dysfunction. In GBM patients, both 
local and systemic immunosuppressive disorders impair any possible antitumor 
response. Woroniecka et al. [5] have analyzed and summarized the categories and 
molecular mechanisms of T-cell dysfunction in GBMs, including senescence, toler-
ance, anergy, exhaustion, and ignorance.
Adoptive T-cell therapy for brain tumors has received increasing attention as 
a breakthrough emerging therapy. Adoptive T-cell therapy refers to engineering 
specific T cells to target the tumor cells and recognize tumor-specific antigens, 
and eventually cause tumor cells to die through the immune response. Because 
T-cell immune response is strong and specific, it can distinguish tumor tissue from 
healthy tissue, and can target malignant cells to prevent distant metastasis, and T 
cells can proliferate to maintain therapeutic effect. Currently, T-cell immunother-
apy includes three types of tumor infiltrating lymphocytes (TIL), T-cell receptor 
(TCR), and chimeric antigen receptor (CAR). Among them, CAR T-cell therapy is 
the only therapy that has made significant progress in clinical application. Chimeric 
antigen receptor T (CAR T) cell therapy refers to using the patient’s own T lympho-
cytes, which have been re-engineered, loaded with receptors and co-stimulatory 
molecules that recognize tumor antigens, and expanded into the patient’s body 
after in vitro expansion to identify and attack their own tumor cell. GBM cells can 
express a variety of antigens, such as human epidermal growth factor receptor 2 
(HER2), interleukin 13 receptor subunit α-2 (IL13Rα2), ephrin-A2 (EphA2), and 
epidermal growth factor receptor variant III (EGFRvIII), which have been suc-
cessfully targeted using chimeric antigen receptors T cells (CARs-T) in preclinical 
models [6].
Studies have shown that CAR T cells targeting EGFRvIII play a role in the treat-
ment of GBM, and multiple trials are ongoing or under preparation. A Phase I study 
involving 10 patients with relapsed GBM demonstrates the safety and feasibility 
of EGFRvIII CAR T-cell therapy [7]. IL13Rα2-CARsT cells can produce cytokines, 
including interferon γ (IFNγ) and tumor necrosis factor-α (TNF-α), and display 
cytolytic activity by generating a pro-inflammatory microenvironment in mice 
bearing gliomas. Phase I trials (NCT00730613) for recurrent GBM have been com-
pleted and promising results have been shown [8]. Another IL13Ra2-targeted CAR 
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T-cell therapy for patients with recurrent GBM has also shown significant effects 
[1–7]. Ahmed and colleagues reported a Phase I study involving 17 HER2 + GBM 
patients treated with HER2-specific CAR-modified virus-specific T cells, which 
achieved safety, feasibility, and anti-GBM activity endpoint [9].
Although CAR T cells have high therapeutic potential, complex GBM biological 
characteristics and tumor microenvironment make CAR T-cell therapy also face 
challenges.
CAR T cells cannot target intracellular proteins, and tumors may shed their 
targets and escape treatment. There may also be insufficient proliferation of T cells, 
resulting in treatment that is not durable. Some researchers are engineering and 
modifying T cells to improve their antitumor efficacy. Interleukin 12 is an effective 
pro-inflammatory cytokine. Yeku designed a CAR T cell that carries and expresses 
IL-12, and proved that the CAR T cell has enhanced proliferation ability, decreased 
apoptosis, and increased cells toxicity, thereby enhancing antitumor efficacy in 
ovarian peritoneal cancer [10]. Kevin Bielamowicz et al. created trivalent T cells 
with three specific CAR molecules (trivalent CAR T cells) to overcome the patient’s 
antigenic variability in glioblastoma. Compared with monovalent and bivalent 
CAR T cells, trivalent CAR T cells mediate powerful immune synapses by forming 
more microtubule tissue centers between CAR T cells and tumor targets, and show 
stronger cytotoxicity according to each patient [6].
In the future, with the continuous deepening of research, adoptive T-cell strategies 
will definitely open up a bright path for GBM immunotherapy.
ALT therapy has now evolved to leverage advances in gene engineering and 
retroviral delivery. Patient-derived T cells can be engineered with antigen-specific 
T-cell receptors (TCRs) or tumor-specific chimeric antigen receptors (CARs) to 
confer target recognition independent of and in addition to naturally occurring 
TCRs. The best studied of these T-cell modifications are CARs. CARs are synthetic 
receptors that couple the single-chain Fv fragment of a monoclonal antibody with 
various T-cell signaling molecules, thus endowing T cells with the antigen-specific 
recognition of the humoral compartment, the intracellular signaling required for 
cytotoxicity, and the co-stimulation necessary for sustained activity. As such, CAR 
T cells recognize target antigens without a need for MHC peptide presentation, 
circumventing one major mechanism of tumor immune escape-MHC downregula-
tion. CAR T-cell therapy has demonstrated promising results and FDA approval for 
hematological malignancy is expected shortly [11].
Clinically, adoptive T-cell therapy has demonstrated its effectiveness with 
CAR-based treatment for CD19C B-cell malignancies. A clinical trial for 11 recur-
rent GBM patients has demonstrated infusions of autologous adoptively transferred 
human cytomegalovirus (CMV)-specific T cells increased OS to > 57 weeks, with 
four patients maintaining no progression throughout the study period [12].
2.2 Peptide vaccine
Peptide vaccination concerns generation of vaccine based on peptide sequences 
representing a tumor antigen-specific target. Peptide vaccinations offer the advan-
tage of high specificity and ease of antigen generation. Limitations include poor 
immunogenicity of peptide [1].
Rindopepimut (CDX-110) is a 14mer amino acid peptide that spans the EGFRvIII 
mutation site conjugated with keyhole limpet hemocyanin (KLH). In a small single-
arm Phase II multicenter trail, 18 patients with newly diagnosed GBM completing 
standard of care therapy were vaccinated with rindopepimut combined with 
granulocyte-macrophage colony-stimulating factor (GM-CSF) resulting in a median 
OS of 26 months [4]. Overall, this vaccine was well tolerated with minimal toxicity.
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Another randomized Phase II trial including 65 newly diagnosed EGFRvIII-
positive patients with GBM was undertaken. Patients again received rindopepimut 
combined with GM-CSF following tumor resection and TMZ chemoradiation. The 
median OS was 24.6 months. Randomized Phase III clinical trial currently under-
way and initial Phase III data showed increased progression-free survival (PFS) and 
OS from point of diagnosis [1].
3. Monoclonal antibodies to EGFRvIII
The epidermal growth factor receptor (EGFR) gene expression is associated 
with a malignant phenotype in multiple cancers, like colon cancer, non-small cell 
lung cancer, head and neck squamous cell carcinoma, and GBM [13].
The EGFR gene amplification has been reported to be the most common genetic 
alteration in primary GBMs (40–70%) [13]. In approximately about 50–60% of 
GBMs with EGFR overexpressed, there is a specific type of EGFR gene variant 
generally called as EGFR variant III (EGFRvIII) [14]. EGFRvIII is the most common 
result of gene rearrangement after EGFR gene amplification [15–17]. Histone modi-
fication of gene enhancer on chromosome 7p12 leads to EGFRvIII formation [18]. 
Juxtaposition of EGFR exon 1 and 8 forms a novel glycine residue between these two 
exons. Deletion of EGFR exon 2–7 yields a truncated transmembrane protein recep-
tor that lacks the extracellular ligand-binding domain but retains the constitutional 
tyrosine kinase activity that stimulates malignant growth [19, 20]. At present, there 
is no evidence of EGFRvIII expression in wild type human tissues [17, 21–25]. Thus, 
EGFRvIII serves as a unique tumor-specific antigen and is a candidate for targeted 
therapy [26]. EGFRvIII can show ligand-independent activity and continuously 
activate downstream signaling pathway [27, 28], which promotes proliferation, 
reduces apoptosis, enhances tumor cell xenograft ability, and increases angiogenesis 
and invasion [22, 27, 29–31].
According to current research, antibodies that target EGFRvIII for the treatment 
of gliomas include ABT-414 and AMG-595.
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-specific selection 
antibody drug conjugate (ADC) composed of an anti-EGFR antibody ABT-806 
and a potent microtubule inhibitor (MMAF). Studies by Philips et al. have shown 
that ABT-414 can selectively kill the tumor cells with EGFRwt or EGFRvIII over-
expressed tumor in vivo xenograft models and in vitro. ABT-414 combined with 
radiotherapy and chemotherapy can significantly inhibit tumor growth in vivo 
[32]. At present, the clinical trials for the treatment of glioma with ABT-414 mainly 
include NCT02343406, NCT02573324, NCT02590263, and NCT01800695.
AMG 595 is an antibody-drug conjugate comprising a fully humanized, anti-
EGFRvIII monoclonal antibody linked to the maytansinoid DM1, a semisynthetic 
derivative of maytansine. AMG595 binds to EGFRvIII but not native EGFR; after 
binding, the AMG595-EGFRvIII complex is internalized via the lysosomal pathway, 
leading to the release of DM1 and mitotic arrest and potent growth inhibition [13]. 
AMG 595 exhibited favorable pharmacokinetics and is a unique therapy with pos-
sible benefit for some patients with EGFRvIII-mutated GBM with limited therapeu-
tic options [26].
4. Immune checkpoint blockade
As early as 1863, Rudolf Virchow reported the inflammatory infiltration in 
tumor tissues and proposed an important connection between cancer and the 
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immune system [33]. In the following researches, the concept of “immune check-
point molecules” was proposed. One of the important physiological functions of the 
immune checkpoint molecule is to keep the activation of the immune system within 
the normal range. Dysfunction of immunological checkpoint molecules can lead to 
immune evasion in many human tumors. Nowadays, immune checkpoint therapies 
are attracting a lot of attention from scientists who are devoted to cancer treatment.
It has been recognized that coinhibitory receptors on T cells play an essential 
role in attenuating the strength and duration of T cell-mediated immune responses. 
These inhibitory receptors are referred to as immune checkpoint molecules, which 
are responsible for maintaining self-tolerance and preventing autoimmune reac-
tions [34]. To date, the two most intensely investigated coinhibitory molecules 
are CTLA-4 (that acts early in T-cell activation) and PD1 (that blocks T cell at late 
stages of the immune response). It has been demonstrated that blockade of CTL4 
and PD1 could induce tumor regression and promote long-term survival in mouse 
glioma models [34].
Among a lot of immune checkpoint molecules, the membrane-bound molecules 
programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) are the two most 
popular markers.
4.1 PD-1 and PD-L1
The programmed cell death ligand 1 (PD-L1) protein belongs to the B7 family, 
and is widely expressed in almost all tumor cells as well as many normal cells. The 
combination of PD-L1 and PD-1 provides a strong inhibitory signal that inhibits the 
proliferation, activation, and infiltration of cytotoxic T lymphocytes (CTLs) [35, 
36], thereby mediating the immunosuppressive effects of tumors. This is consid-
ered to be the major negative regulatory mechanism of CTLs in the cancer microen-
vironment. More importantly, in addition to binding to PD-1, PD-L1 can also bind 
to other co-stimulatory molecules such as CD28, CD80, and CTLA-4 in cancer cells 
[37], which indicates that PD-L1 can mediate a broader and more complex immune 
regulation mechanism. Therefore, it is important to analyze the expression and cell 
distribution of PD-L1 in GBM tissues.
Glioblastoma (GBM) creates immune evasion and suppression, thereby evad-
ing the body’s immune system and promoting tumor growth. Despite standard 
management composed of the maximal surgical resection with the combination of 
radiation therapy and chemotherapy, the median survival time of GBM patients is 
only 12–15 months after diagnosis [38]. At present, it is found that immunological 
checkpoint proteins can be blocked by related checkpoint inhibitors, thus becom-
ing a viable target for tumor therapy. Therefore, it is very meaningful to explore 
new immunotherapy to counteract the immunosuppressive effects in GBM, and 
necessary to explore new immunotherapy to counteract the immunosuppressive 
effects in GBM.
4.2 Expression and cell distribution of PD-L1 in human glioma tissues
The PD-1 ligand, PD-L1 (also known has B7-H1), has been observed to be 
expressed in GBMs and GBM-associated macrophages, but the positivity rate in GBMs 
is controversial and highly variable, probably due to the selections of different anti-
bodies by those researches [34, 39, 40]. Berghoff et al. [41] used a non-commercial 
anti-PD-L1 antibody, 5H1, showed membranous PD-L1 expression in 37.6% of newly 
diagnosed and 16.7% of recurrent GBMs, and diffuse/fibrillary PD-L1 expression 
in 84.4% of newly diagnosed and 72.2% of recurrent GBMs. However, in a study 
with 1035 GBM specimens using SP142 antibody, the positive rate of PD-L1 was only 
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19% [42]. Our own data, using the same standard in NSCLC (cutoff value was ≥1% 
of tumor cells expression), showed PD-L1 (clone number 28-8) expressed in 52% 
(69/133) of GBMs (see Figure 1).
4.3 Prognostic value of PD-L1 in GBM patients
Many studies have investigated the association between PD-L1 expression 
levels and the prognosis of GBM patients. But the results from different studies 
are non-conclusive. Nduom et al. [43] discovered that positive PD-L1 expression 
was associated with a poor prognosis, though this result has limited significance. 
Two recent studies have suggested that positive PD-L1 immunostaining in human 
GBM tissue means a poor prognosis [44, 45]. However, Berghoff et al. proposed 
the PD-L1 was not a negative predictor of survival [41], and Lee et al. [46] found 
the PD-L1 expression did not appear to be an independent factor for unfavorable 
prognosis according to multivariate analysis.
Efforts aimed at inhibiting the PD-1/PDL1 pathway have shown more promising 
results. In a preclinical study using the GL261 glioma mouse model, combination 
of anti-PD-1 antibodies and radiotherapy doubled median survival and elicited 
long-term survival in 15–40% of mice compared with either treatment alone [34]. 
Clinically, pembrolizumab, a PD-L1 antibody has been approved by the FDA, to 
apply in the treatment of metastatic melanoma and NSCLC. In GBM, nivolumab, 
another PD-1 antibody, developed for GBM patients is being tested with two clini-
cal trials [34].
A randomized Phase III study aimed at testing nivolumab versus bevacizumab 
in recurrent GBM patients will also test combination therapy of nivolumab and 
ipilimumab. Another two Phase I/II trials will analyze the effectiveness of combina-
torial pembrolizumab and bevacizumab, and combinatorial pembrolizumab with 
MRI-guided laser ablation in recurrent GBM patients. In addition, MED14736, a 
humanized PD-L1 mAb, is currently being tested in clinical trials for GBM patients 
combined with radiotherapy and bevacizumab [34].
Currently, immunological checkpoint inhibitor drugs associated with PD-L1 for 
the treatment of glioblastoma are undergoing relevant clinical trials. Nivolumab is 
a fully humanized IgG4 subtype programmed death-1 (PD-1) immune checkpoint 
inhibitor antibody that binds with high affinity to PD-1 receptors on T cells and 
blocks their interaction with PD-L1 and restores T-cell antitumor function. There 
are several clinical trials of nivolumab for GBMs. The first large-scale randomized 
clinical trial of Checkmate 143(NCT 02017717) evaluated the safety and efficacy 
Figure 1. 
The positive staining of PD-L1 in tumor cells by immunohistochemical stain. The brown color of the glioma cell 
membrane indicates the positive staining.
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of nivolumab in GBM patients. In addition, the trial included a study comparing 
nivolumab monotherapy with bevacizumab in patients with recurrent GBM [47]. 
However, in the third phase of the clinical trial, 369 patients with first recurrence 
of GBM were recruited and it was found that nivolumab failed to prolong OS in 
patients compared with bevacizumab [48].
Pembrolizumab is another humanized monoclonal IgG4 anti-PD-1 antibody. 
Pembrolizumab was evaluated in 29 patients with high-grade malignant gliomas, 
including overall response rate (ORR) on contrast MRI, characterizing toxicities, 
progression-free survival (PFS), and overall survival (OS) [49]. Another trial about 
pembrolizumab showed that this drug is well tolerated, but the anti-PD-1 mono-
therapy was not effective for most GBM patients [50, 51].
In addition, other PD-L1 immune checkpoint inhibitor drugs for GBM that 
are being studied include durvalumab, atezolizumab, pidilizumab, and so on. 
Durvalumab is a fully humanized immunoglobulin G1k monoclonal antibody that 
blocks the binding of PD-L1 to PD-1 and CD80, thereby enhancing the identifica-
tion and killing of tumor cells by T cells. Atezolizumab is a humanized immuno-
globulin G1 (IgG1) monoclonal antibody directly targeting PD-L1. It prevents the 
interaction of PD-L1 with the receptors PD-1 and B7.1 by binding to L1. Currently, 
three open clinical trials (NCT 01375842, NCT02458638, and NCT03174197) are 
investigating atezolizumab in GBM patients. Pidilizumab is a humanized immu-
noglobulin (Ig) G1 monoclonal antibody directed against human PD-1 to block the 
combination between PD-1 and its ligands, PD-L1 and PD-L2. NCT01952769 is an 
ongoing clinical trial evaluating pidilizumab for GBM [52].
In future, besides PD-L1, more immune checkpoint inhibitors will be put into 
clinical trials to target this highly malignant brain tumor in future. Overall, the 
combination of various immune checkpoint modulators has shown promising 
effectiveness in the treatment of some solid tumors. The application of combinato-
rial checkpoint modulators in GBM and other tumors therefore requires further 
investigation into the interplay of co-stimulatory and coinhibitory molecules [34].
5. Conclusion
Although still in its infancy, immunotherapy for cancers has already shown 
significant effect against some types of malignancy, such as melanoma and lung 
cancer. Current open clinical trials of immunotherapy for GBM predominantly 
focus on dendritic cell (DC) vaccines and antibodies targeting immunosuppres-
sive checkpoints have achieved promising immune activity and clinical responses. 
However, durable and sustained response remains rare, highlighting the need for 
novel promising approaches including gene therapy and combinatorial immuno-
therapeutic treatment [12].
Current obstacles for immune therapy for GBM lie in: (1) finding drugs to pen-
etrate the BBB; (2) identifying specific, suitable, and immunogenic tumor antigens; 
and (3) identifying appropriate pre- and post-therapeutic biomarkers to reliably 
evaluate the treatment effect [34]. Additional research is necessary in the future 
to overcome those difficulties and identify a good treatment option or options for 
patients with GBM.
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